News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
283,191 Results
Type
Article (15393)
Company Profile (307)
Press Release (267491)
Section
Business (83948)
Career Advice (166)
Deals (14111)
Drug Delivery (36)
Drug Development (53723)
Employer Resources (32)
FDA (7067)
Job Trends (5689)
News (154800)
Policy (11618)
Tag
Academia (1015)
Alliances (22739)
Alzheimer's disease (770)
Approvals (7047)
Artificial intelligence (70)
Bankruptcy (115)
Best Places to Work (5049)
Biotechnology (250)
Breast cancer (118)
Cancer (933)
Cardiovascular disease (74)
Career advice (145)
CAR-T (76)
Cell therapy (223)
Clinical research (42920)
Collaboration (322)
Compensation (133)
COVID-19 (1369)
C-suite (79)
Cystic fibrosis (78)
Data (1045)
Diabetes (88)
Diagnostics (1584)
Drug discovery (61)
Earnings (31188)
Events (49624)
Executive appointments (261)
FDA (7489)
Funding (318)
Gene editing (64)
Gene therapy (168)
GLP-1 (321)
Government (1370)
Healthcare (7128)
Infectious disease (1443)
Inflammatory bowel disease (99)
IPO (7630)
Job creations (936)
Job search strategy (138)
Layoffs (208)
Legal (1571)
Lung cancer (138)
Lymphoma (68)
Manufacturing (92)
Medical device (3263)
Medtech (3264)
Mergers & acquisitions (6618)
Metabolic disorders (269)
Neuroscience (1025)
NextGen Class of 2024 (2154)
Non-profit (924)
Northern California (1114)
Obesity (148)
Opinion (93)
Parkinson's disease (79)
Patents (66)
People (26065)
Phase I (14600)
Phase II (19592)
Phase III (13235)
Pipeline (385)
Postmarket research (1103)
Preclinical (6160)
Radiopharmaceuticals (206)
Rare diseases (216)
Real estate (1502)
Regulatory (9509)
Research institute (1002)
Southern California (1010)
Startups (2022)
United States (9208)
Vaccines (276)
Weight loss (87)
Date
Today (15)
Last 7 days (46)
Last 30 days (1334)
Last 365 days (21644)
2024 (21644)
2023 (23702)
2022 (28812)
2021 (30085)
2020 (26329)
2019 (17481)
2018 (12768)
2017 (14893)
2016 (12883)
2015 (15410)
2014 (11173)
2013 (8112)
2012 (8206)
2011 (8324)
2010 (8042)
Location
Africa (158)
Asia (18132)
Australia (3109)
California (2553)
Canada (841)
China (212)
Colorado (100)
Connecticut (116)
Delaware (69)
Europe (39808)
Florida (297)
Georgia (83)
Illinois (170)
Indiana (74)
Maryland (365)
Massachusetts (2042)
Minnesota (102)
New Jersey (695)
New York (707)
North Carolina (456)
Northern California (1114)
Ohio (89)
Pennsylvania (532)
South America (230)
Southern California (1010)
Texas (289)
Washington State (252)
283,191 Results for "respira therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Respira Therapeutics Announces First Patient Dosed in Phase 2b VIPAH-PRN 2b Trial of RT234 in Patients with Pulmonary Arterial Hypertension (PAH)
Respira Therapeutics, Inc. announced today that the first patient in the United States has been dosed in the multicenter trial of its lead product candidate, RT234-PAH (vardenafil administered as a dry powder inhaled treatment).
April 5, 2022
·
4 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Business
Respira Technologies, Inc. Announces Partnership With The Plough Center For Sterile Drug Delivery At The University Of Tennessee Health Science Center
Respira Technologies, Inc. announced , its partnership with the Plough Center for Sterile Drug Delivery at the University of Tennessee Health Science Center to execute aseptic drug product handling and cartridge filling to support the companies planned IND submission to the FDA and to prepare for human clinical studies.
March 22, 2022
·
3 min read
Biotech Bay
Latina-Led Respira Labs Raises $2.8 Million to Revolutionize Respiratory Care for COPD, COVID-19 and Asthma Patients
Respira Labs today announces it has closed $2.8 million to continue to develop and produce its chest wearable that uses acoustic resonance to assess lung function and identify changes in lung air volume, which is especially critical for COPD, COVID-19, and asthma patients.
February 10, 2022
·
3 min read
Business
Altasciences Chosen by Respira Technologies, Inc. as Drug Product Manufacturing Partner for the World’s First Inhaled Nicotine Replacement Therapy (NRT)
Altasciences’ pharmaceutical contract manufacturing site in Philadelphia, PA, has been chosen by Respira Technologies, Inc. to manufacture proprietary drug products for the world’s first inhaled smoking cessation therapy.
December 14, 2021
·
2 min read
Press Releases
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions
December 10, 2024
·
6 min read
Press Releases
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels
December 12, 2024
·
10 min read
Business
Respira Technologies, Inc. announces Brian W. Quigley, former CEO of Altria Group’s Smokeless Division, to join as Chief Operating Officer
Respira Technologies, Inc. (“Respira”), is pleased to announce Brian W. Quigley, a sixteen year veteran of Altria Group Inc., is joining Respira’s management
June 30, 2020
·
3 min read
Regulatory
FDA Warns Applied Therapeutics of ‘Objectionable Conditions’ in Govorestat Study
The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical trial—including a dosing error for govorestat—claims that the company said it had already addressed.
December 4, 2024
·
2 min read
·
Tristan Manalac
Bio NC
Vast Therapeutics Selected to Present at the American Thoracic Society (ATS) 2024 Respiratory Innovation Summit
Vast Therapeutics, a clinical-stage life science company focused on breaking the debilitating cycle of chronic infection and inflammation in respiratory diseases, today announced an upcoming presentation at the 2024 Respiratory Innovation Summit being held in San Diego May 17-18, 2024.
April 17, 2024
·
1 min read
1 of 28,320
Next
